COR 116 Pill: What Is It?

Mixed amphetamine salts 10mg — blue round tablet — CorePharma LLC — Schedule II stimulant

Identifying the COR 116 Pill

The imprint COR 116 appears on a blue, round tablet containing mixed amphetamine salts (MAS) 10mg, manufactured by CorePharma LLC, a New Jersey-based generic pharmaceutical company. The "COR" prefix is CorePharma's registered manufacturer imprint code, and 116 identifies the specific product and strength within their catalog.

This tablet is a generic equivalent of Adderall 10mg, the brand-name mixed amphetamine salts product historically associated with Shire Pharmaceuticals (now Takeda). Generic mixed amphetamine salts tablets entered the U.S. market after relevant formulation patents expired and now account for the majority of amphetamine salt prescriptions dispensed in the United States.

The blue color of the COR 116 tablet follows a color convention for the 10mg amphetamine strength — the same color used by the branded Adderall 10mg product. When patients transition between brand and generic, or between generic manufacturers, they may notice differences in the pill's exact shade of blue, size, or texture, while the active pharmaceutical ingredients remain identical.

What Are Mixed Amphetamine Salts?

Mixed amphetamine salts (MAS) is a proprietary combination of four amphetamine salt forms in specific ratios:

• Amphetamine aspartate monohydrate
• Amphetamine sulfate
• Dextroamphetamine saccharate
• Dextroamphetamine sulfate

The formulation contains 75% dextroamphetamine (d-amphetamine) salts and 25% levoamphetamine (l-amphetamine) salts by total amphetamine base weight. Dextroamphetamine is significantly more potent for central nervous system stimulation, while levoamphetamine has comparatively more peripheral cardiovascular activity. The combination is believed to produce a smoother onset and more balanced duration profile compared to pure dextroamphetamine alone.

Amphetamines work primarily by stimulating the release of monoamine neurotransmitters — dopamine, norepinephrine, and to a lesser extent serotonin — from presynaptic terminals, while simultaneously blocking their reuptake transporters. The net result is elevated concentrations of these neurotransmitters in synaptic spaces throughout the brain, leading to enhanced attention, reduced impulsivity, and improved executive function in individuals with ADHD.

FDA-Approved Indications

Mixed amphetamine salts are FDA-approved for two conditions:

• Attention Deficit Hyperactivity Disorder (ADHD) — indicated in children aged 3 years and older, adolescents, and adults
• Narcolepsy — indicated in adults and children 6 years and older

ADHD is one of the most prevalent neurodevelopmental conditions, affecting an estimated 5–7% of children and 2–5% of adults worldwide. It is characterized by persistent patterns of inattention, hyperactivity, and impulsivity that impair functioning across multiple life domains. Stimulant medications, including mixed amphetamine salts, represent the first-line pharmacological treatment for ADHD across age groups, supported by decades of clinical evidence.

Narcolepsy is a neurological disorder involving excessive daytime sleepiness, sudden muscle weakness triggered by emotion (cataplexy), sleep paralysis, and hallucinations at sleep onset. Amphetamine stimulants promote wakefulness by enhancing dopaminergic and noradrenergic signaling in arousal circuits.

About CorePharma LLC

CorePharma LLC is headquartered in Middlesex, New Jersey, and has been operating as a generic pharmaceutical manufacturer since 2001. The company specializes in controlled substance generics and holds multiple DEA Schedule II manufacturing licenses. CorePharma's portfolio includes amphetamine combination products, methylphenidate formulations, and other CNS-active medications requiring the highest level of DEA regulatory oversight.

The company markets products both under its own CorePharma label and through private label and distribution agreements. Their "COR" imprint prefix is registered with the FDA's drug labeling database and identifies all CorePharma solid oral dosage products. Manufacturing operations are conducted under Current Good Manufacturing Practice (cGMP) standards with regular FDA inspection.

Schedule II Status and the Amphetamine Shortage

Amphetamines are classified as DEA Schedule II controlled substances, reflecting their high potential for abuse and dependence alongside accepted medical use. This classification subjects them to DEA production quotas — annual limits on the quantity each manufacturer may produce. These quotas contributed significantly to the nationwide amphetamine shortage that began in late 2022 and persisted through much of 2024, during which many patients reported difficulty filling their prescriptions.

The shortage prompted patients to accept prescriptions from different generic manufacturers than they were accustomed to, leading to increased confusion about pill appearances and imprints. A COR 116 tablet may look different from the Adderall a patient was previously dispensed, even though both are the same drug and strength. This is normal and expected when switching between manufacturers.

Amphetamine medications have significant misuse potential, particularly for non-prescribed cognitive enhancement or euphoric effects. Patients should store COR 116 tablets securely and dispose of unused medication through DEA-authorized take-back programs or using FDA-approved drug disposal pouches.

Key Drug Interactions and Safety Considerations

Mixed amphetamine salts interact with several important drug classes. Monoamine oxidase inhibitors (MAOIs) are absolutely contraindicated with amphetamines due to the risk of a potentially fatal hypertensive crisis or serotonin syndrome; a minimum 14-day washout period is required after discontinuing an MAOI before starting amphetamine therapy.

Amphetamines can raise blood pressure and heart rate. The FDA advises against their use in patients with pre-existing serious structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, or coronary artery disease. The FDA also carries a black box warning regarding the high potential for abuse and dependence.

Urinary pH affects amphetamine excretion: acidifying agents (ammonium chloride, vitamin C in high doses) can significantly reduce amphetamine effect duration by accelerating renal elimination, while alkalinizing agents (sodium bicarbonate, acetazolamide) slow elimination and prolong effects.

Frequently Asked Questions